Emily M. Leproust Sells 1,726 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 1,726 shares of the business’s stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $41.68, for a total value of $71,939.68. Following the completion of the transaction, the chief executive officer now owns 660,966 shares in the company, valued at approximately $27,549,062.88. This trade represents a 0.26 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Twist Bioscience Stock Performance

NASDAQ:TWST traded up $2.05 during midday trading on Monday, reaching $44.94. 724,963 shares of the company traded hands, compared to its average volume of 924,609. The firm has a market capitalization of $2.68 billion, a price-to-earnings ratio of -13.30 and a beta of 2.15. The company has a fifty day moving average price of $45.40 and a 200 day moving average price of $45.27. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62. Twist Bioscience Co. has a twelve month low of $27.41 and a twelve month high of $60.90.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The company had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. During the same quarter in the previous year, the company posted ($0.75) earnings per share. The company’s revenue for the quarter was up 24.1% compared to the same quarter last year. On average, analysts expect that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Institutional Investors Weigh In On Twist Bioscience

Several large investors have recently made changes to their positions in the company. Wilmington Savings Fund Society FSB acquired a new position in shares of Twist Bioscience during the third quarter worth approximately $34,000. Van ECK Associates Corp raised its stake in Twist Bioscience by 56.4% during the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock valued at $34,000 after acquiring an additional 267 shares in the last quarter. Banque Transatlantique SA acquired a new position in Twist Bioscience during the 4th quarter worth $43,000. GF Fund Management CO. LTD. bought a new position in shares of Twist Bioscience in the fourth quarter worth $58,000. Finally, US Bancorp DE increased its holdings in shares of Twist Bioscience by 72.0% during the fourth quarter. US Bancorp DE now owns 1,436 shares of the company’s stock valued at $67,000 after purchasing an additional 601 shares during the period.

Analysts Set New Price Targets

Several equities analysts have recently commented on TWST shares. Scotiabank reiterated an “outperform” rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Wolfe Research assumed coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price for the company. Barclays set a $58.00 price target on shares of Twist Bioscience and gave the stock an “overweight” rating in a research report on Monday, February 3rd. Robert W. Baird boosted their price objective on Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a report on Tuesday, February 4th. Finally, JPMorgan Chase & Co. increased their target price on Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a report on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $54.40.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.